1

4th annual

IMMUNO-ONCOLOGY Young Investigators’ Forum

An Academic Research Forum Focusing on Research and Career Development for

Oncology Junior Faculty and Fellows

www.IOYIF.comFollow us on Twitter @IOYIForum

PROGRAM NEWSLETTER

Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. in collaboration with the Society for Immunotherapy of Cancer.

This activity is supported by an independent educational grant from AstraZeneca.

1

Message from the Activity Chairs

Dear Colleagues,

Immune modulation is one of the most promising therapeutic approaches for many different types of cancer. The broad activity already demonstrated for immune checkpoint inhibitors and cellular therapies is stimulating the development of multiple new immunotherapy agents and a dramatic expansion of both basic/translational and clinical/translational research. To maintain and expand these research efforts, we need to train Young Investigators in this field to meet cur-rent and future challenges. The Fourth Annual Immuno-Oncology Young Investigators’ Forum brought together investi-gators in their formative years with a research focus in immuno-oncology to provide training and insight into this prom-ising therapeutic area. A world-class group of Expert Faculty Judges selected 35 Young Investigators (clinician scientists, research scientists, PhD/postdoctoral researchers, and clinical fellows) based on submission of a blinded abstract. The investigators presented their research and received constructive critiques from the Expert Faculty Judges. We incorpo-rated professional coaching and mentoring as a central feature of the meeting.

The research presented at the meeting was representative of the many investigational areas of immuno-oncology and included the hottest topics in the field, specifically immune checkpoint inhibitors such as anti-PD-1/PD-L1, CAR-T, and novel cell therapies.

The Fourth Annual Immuno-Oncology Young Investigators’ Forum was deemed a success. The veteran Expert Faculty Judges commented that “compared to other national meetings, the abstracts presented here are of a higher caliber.” Young Investigators identified several special highlights of the program. They gained insight into academic career development from comments and direction on their research provided by the Expert Faculty Judges during the presentations and social events, and also from talks by expert faculty on their personal career development and challenges.

We could not have been more impressed by the sophistication of research being conducted by this group of Young Investigators, the high quality of their research ideas, the maturity demonstrated in presenting and addressing questions raised by the Expert Faculty Judges, and their desire to make a major difference in advancing the treatment of cancer.

On behalf of the Expert Faculty Judges, we take this opportunity to congratulate the Young Investigators on their accom-plishments and wish them the very best for continuing success.

Sincerely,

Mario Sznol, MDProgram Co-chair

Patrick Hwu, MDProgram Co-chair

DearColleagues,

Immunemodulation isoneof themostpromising therapeuticapproaches formanydifferenttypesofcancer.Thebroadactivityalreadydemonstratedforimmunecheckpointinhibitorsandcellulartherapiesisstimulatingthedevelopmentofmultiplenewimmunetherapyagents,andadramaticexpansionofbothbasic/translational andclinical research.Tomaintainandexpandthese researchefforts,weneed to trainyoung investigators in this field tomeetcurrentandfuture challenges. The Third Annual Immuno-Oncology Young Investigators’ Forum broughttogether investigators in their formative yearswith a research focus in immuno-oncology toprovidetrainingandinsightintothispromisingtherapeuticarea.Aworld-classfacultyselected40younginvestigators(juniorfacultyandfellows)basedonsubmissionofanabstract.The40investigators presented their research and received constructive critiques from the expertfaculty.Weincorporatedcareeradviceandmentoringasacentralfeatureofthismeeting.

Theresearchpresentedatthemeetingwasrepresentativeofthemanyinvestigationalareasofimmune-oncologyand includedthehottesttopics inthefield,specifically immunecheckpointinhibitorssuchasanti-PD-1/PD-L1andnovelcelltherapies.

TheThirdAnnualImmuno-OncologyYoungInvestigators’Forumwasverysuccessful.Theveteranexpert faculty members commented that “the quality of the science and the elegantpresentations were superb.” Young investigators identified several special highlights of theprogram.Theygainedinsightintoacademiccareerdevelopmentfromcommentsanddirectionontheirresearchprovidedbytheexpertfacultyduringthepresentationsandsocialevents,andalsofromtalksbyexpertfacultyontheirpersonalcareerdevelopmentandchallenges.

Asfacultymembers,wecouldnothavebeenmoreimpressedbythesophisticationofresearchbeingconductedbythisgroupofyounginvestigators,thehighqualityoftheirresearchideas,thematuritydemonstratedinpresentingandaddressingquestionsraisedbytheexpertfaculty,andtheirdesiretomakeamajordifferenceinadvancingthetreatmentofcancer.

Onbehalfoftheexpertfaculty,wetakethisopportunitytocongratulatetheyounginvestigatorsontheiraccomplishmentsandwishthemtheverybestforcontinuingsuccess.

Sincerely,

MarioSznol,MD PatrickHwu,MDProgramChairProgramCo-Chair

2018 Young Investigators and Expert Faculty Judges

2

The Immuno-Oncology Distinguished Young Investigator Award $10,000 Grant

The Immuno-Oncology Distinguished Young Investigator Award provides recognition for Junior Faculty who contin-ue their dedication and sustained research efforts in immunotherapy. This year’s Immuno-Oncology Distinguished Young Investigators’ Awards were presented to:

2018 JUNIOR FACULTY—RESEARCH SCIENTIST WINNERAaron Ring, MD, PhD Yale University School of Medicine, New Haven, Connecticut

Research Title: “Decoy-resistant” Interleukin-18 Overcomes the Soluble Immune Checkpoint IL-18BP to Unlock a Potent Immunotherapeutic Cytokine Pathway

Dr. Ring received his undergraduate training at Yale University where he graduated with concurrent master’s and bachelor’s degrees in molecular biophysics and biochemistry in 2008. He then entered the Medical Scientist Training Program at Stan-ford University School of Medicine. At Stanford, he worked in the laboratories of K. Christopher Garcia and Irving Weissman to develop new cytokine and immune checkpoint therapies for cancer, receiving his medical degree and doctorate in 2016. Dr. Ring joined the faculty of the Yale Department of Immunobiology in 2016 as the Robert T. McCluskey Yale Scholar and supported by an NIH Director’s Early Independence Award. The focus of his research is to understand and manipulate the activity of immune receptors using structural biology and protein engineering. With these approaches, his lab can create new pharmacologic tools, such as engineered cytokines, that can be used to dissect complicated immunoregulatory pathways in the tumor microenvironment. Additionally, these engineered proteins may hold promise as therapeutic drug candidates for clinical development.

“The IOYIF was a phenomenal opportunity to not only get feedback on our work at a key early time-point, but also to meet luminar-ies in the immuno-oncology field and rising stars that I hope to collaborate with in the future.”

“The IOYIF award will be used to perform a series of high-risk/high-reward studies that have been on our wish-list for a while. We hope the results will spur new research directions for cytokine-based cancer immunotherapy.”

2018 JUNIOR FACULTY—CLINICIAN SCIENTIST WINNERRobin Parihar, MD, PhD Baylor College of Medicine, Houston, Texas

Research Title: Natural Killer Cells Targeting the Suppressive Immune Microenvironment Rescue the Impaired Activity of CAR T-cells within Solid Tumors

Dr. Parihar is a pediatric oncologist with an interest in caring for children with solid tumors. In addition, he has an active research lab interested in stimulating the immune system to fight cancer. His lab investigates the role of a specific type of immune cell called the natural killer (NK) cell in the control of solid tumors. His research program aims to enhance NK cell function to target the solid tumor microenvironment, essentially getting rid of the accessory cells that help tumors resist standard therapies. Efforts are ongoing to introduce the enhanced NK cells as therapy for patients with advanced cancers. In addition, Dr. Parihar has established unique models to better understand how the tumor microenvironment suppresses the immune system, in order to develop new approaches to overcome this inhibition and improve standard and immune-based therapies for solid tumors.

“The IOYIF was an incredible experience that allowed networking with peers and contemporary luminaries in the immuno- oncology field. I was able to appreciate the breadth of work going on in the field and cultivate new collaborations and ideas.”

“I plan to use the award for research-related travel and lab supplies.”

3

2018 Junior Faculty Winners RESEARCH SCIENTIST

1st PlaceAnthony Rongvaux, PhD Fred Hutchinson Cancer Research Center

Research Title: The Role of Macrophages in Metastatic Cancer

“Participating in the IOYIF was a fantastic opportunity to meet colleagues in the immuno-oncology field. The feedback and mentoring from the Faculty Judges definitely will help us make the best decisions for future research direc-tions. And I am convinced that we will frequently meet and collaborate with Young Investigators met during this forum.”

“We will continue to investigate the mechanism by which macrophages influence tumor progression. Once our project ap-proaches completion, we will use the funds from this award to present our work at a scientific conference and certainly obtain valuable feedback from our colleagues.”

2nd PlaceAmaia Lujambio, PhD Icahn School of Medicine at Mount Sinai

Research Title: ß-catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

“Attending the IOYIF was a really great experience at several levels. I met wonderful scientists who are in the early stages of their careers and will be my colleagues in the years to come. I also was able to interact with world-leading experts in immuno-oncology and set some potential collaborations. Finally, the scientific level of the meeting was outstanding, and I was able to learn a lot!”

“We plan to use the grant award to perform an experiment testing CTNNB1 inhibitors in our in vivo model, which was suggest-ed by the Expert Faculty Judges and could potentially have a great translational impact in liver cancer patients.”

3rd PlaceSarwish Rafiq, PhD Memorial Sloan Kettering Cancer Center

Research Title: Enhancing CAR T-cell Anti-tumor Efficacy Through Secreted Single-chain Variable Fragment (scFv) Immune Checkpoint Blockade

“Participating in the IOYIF will impact positively on my professional development because it provided me the opportunity to network with early career and established scientists. I will use the advice and insight I received to move forward in my career.”

“I plan to use part of the grant award to cover membership to SITC and the rest to cover going to scientific meetings.”

4

2018 Junior Faculty Winners CLINICIAN SCIENTIST

1st PlaceSangeetha Meda Reddy, MD, MSCI MD Anderson Cancer Center

Research Title: Phase II Trial of Neoadjuvant Followed by Adjuvant Checkpoint Blockade in High-Risk Resectable Melanoma

“The IOYIF gave me a forum to learn how to better communicate my scientific findings, provided an opportunity to network with future colleagues, and was a great resource to get advice from successful mentors.”

“I will be using the money to attend educational conferences such as ASCO and SITC.”

2nd PlaceBabak Moghimi, MD Children’s Hospital of Los Angeles

Research Title: GD2 Specific Murine CAR T-cells Show Efficacy in Immunocompetent TH-MYCN Neuroblastoma Murine Model

“The IOYIF was a great opportunity to meet successful colleagues and faculty in my field. Learning from their experiences im-proves my ability to tailor a better roadmap to reach my career goals. I would be emphasizing on building collaborations and reaching beyond my comfort zone to advance my scientific work.”

“I plan to use the award for research supplies.”

3rd PlaceRahul A. Sheth, MD MD Anderson Cancer Center

Research Title: Molecularly Targeted Photothermal Ablation for Tumor-specific Adaptive Immunity in Hepatocellular Carcinoma

“Participating in the IOYIF was a transformative experience. As an interventional radiologist, my clinical and research training has primarily focused on the imaging and procedural aspects of cancer care. Image-guided interventions play an important role in the treatment of localized disease, but the influence of these therapies on local tumor microenvironments and the im-mune system is incompletely understood. Exploring these critical questions requires a thorough understanding of contempo-rary cancer biology and immunology. IOYIF provided an unparalleled opportunity to interact with both rising stars and world leaders in these fields. Over the course of just a few days, my understanding of the current state of the art as well as future possibilities advanced exponentially. I am deeply grateful for this experience, and I know that the knowledge and connections that I made during IOYIF will have a positive impact on my career for years to come.”

“The grant funds will be used to further pursue experiments that explore the immunologic ramifications of tumor-specific hyperthermia in hepatocellular carcinoma.”

5

2018 Fellows Winners PHD/POSTDOCTORAL RESEARCHER

1st PlaceTriparna Sen, PhD MD Anderson Cancer Center

Research Title: DNA Damage Repair Targeting Upregulates PD-L1 Level and Potentiates: The Effect of PD-L1 Blockade in Small Cell Lung Cancer

“Attending and presenting my work at the IOYIF has been a wonderful experience for me. I got valuable feedback for my work during my presentation and throughout the workshop, which helped me immensely in improving my research. The workshop provided the opportunity to interact with the leaders in the field who provided inputs regarding career development, academic job search, navigating our research, and work-life balance.

I had the opportunity to meet researchers from all over the country whose work truly impressed me. This workshop helped me establish long-term collaborations with them, and I hope to continue building on these connections in the future”

“I plan to use this award in advancing preclinical studies in understanding the role of DNA damage repair in anti-tumor immune response.”

2nd PlaceShabnum Patel, PhD The George Washington University

Research Title: Gene Modified HIV-specific T-cells Display Resistance to Infection: Therapeutic Applications for HIV+ Individuals with Malignancies Post-BMT

”We had the opportunity to meet scientists from all over the country who are producing high quality immuno-oncology research. We networked and have connected on social media and linked in since the meeting, and plan to keep in touch when attending future related scientific meetings where we will all be in attendance. It was also an excellent opportunity to meet successful and established faculty who provided feedback on not only career development, but work-life balance, and how to navigate academic settings.”

“I plan to use this award to push our pre-clinical studies, generating HIV-specific T-cells from HIV seronegative donors, to the clinical setting.”

3rd Place (tie)Netonia Marshall, PhD Icahn School of Medicine at Mount Sinai

Research Title: Immunotransplant Modulates the IL-2/7/15 Axis and Increases Anti-cancer Efficacy Compared to Checkpoint Blockade or BMT Alone

“Participating in the IOYIF has positively impacted my career by allowing me the opportunity to receive invaluable career advice from some of the leaders of my field. I am at the end of my postdoctoral fellowship and I am trying to determine the next steps of my career. This conference was perfectly timed to allow me the chance to ask questions and career advice and help me figure out my next steps. This conference has been a great help to me and I am thankful to have attended.”

“The grant money will be used as a travel grant to help fund my travel to the next conference that I attend.”

6

2018 Fellows Winners

3rd Place (tie)Meenu Sharma, PhD MD Anderson Cancer Center

Research Title: NKTR-214, an Engineered IL-2 Cytokine, Synergizes with Vaccination to Promote Anti-tumor Immunity in Treatment of Melanoma and Colon Carcinoma

“Being part of the IOYIF was a very enriching experience. The guidance that I received from experienced mentors gave me new per-spective to think and develop my current research work. It certainly gave me the direction for my career path. In addition, it was moti-vating to listen to ongoing clinical work in cancer immunotherapy. Working in a research lab gave us great inspiration to see clinical and translational aspects of our research work.”

“I will use the award for my skill development by spending the award money to attend a training course in advanced flow cytometry.”

7

2018 Fellows Winners CLINICAL FELLOW

1st PlaceTanner M. Johanns, MD, PhD Washington University School of Medicine

Research Title: Identification of Neoantigen-specific T-cells Following a Heterologous Prime-boost Personalized Vaccination Strategy in a Patient with Glioblastoma

“Participating in the forum provided an opportunity to network with experts and peers in the field of immuno-oncology. The feedback and connections will hopefully lead to future collaborations.”

“I will apply the funds to ongoing clinical studies.”

2nd PlaceRavi Bhasker Patel, MD, PhD University of Wisconsin

Research Title: Systemic Delivery of Molecular Targeted Radiotherapy (MTRT) Improves Efficacy of Anti–CTLA-4 in a Murine Melanoma Model

“I really enjoyed the conference and meeting the faculty as well as many of the other participants. I hope to collaborate with several of them, and I think this conference was a very positive experience for my professional development.”

“I hope to potentially use the award for another workshop or further professional development.”

3rd PlaceDenis Migliorini, MD University of Pennsylvania

Research Title: Universal Xenogeneic CAR T-cells: A Novel Translational Platform Using Gene Editing of Human CAR T-cells to Target Canine Tumors

“My participation in the IOYIF gave me the opportunity to meet experts in the field of immunotherapy oncology and learn from amazing sessions of mentorship that will be helpful for my future endeavors and how I plan to conduct my research.”

“I plan to use the award for lab expenses especially for CRISPR guides oligonucleotides.”

8

2018 IOYIF Participants and Institutions Elena Rodriges Blanko, PhDMD Anderson Cancer CenterHouston, Texas

Sandra Cascio, PhDUniversity of Pittsburgh School of MedicinePittsburgh, Pennslyvania

Limo Chen, PhDMD Anderson Cancer CenterHouston, Texas

Stephanie Dorta-Estremera, PhDMD Anderson Cancer CenterHouston, Texas

Jeremy Force, DODuke University Durham, North Carolina

Robyn Gartrell, MDColumbia University Medical CenterNew York, New York

Aurelie Hanoteau, PhDBaylor College of MedicineHouston, Texas

Islam Hassan, MDMD Anderson Cancer CenterHouston, Texas

Sachin R. Jhawar, MD, MSCIRutgers Cancer Institute of New Jersey New Brunswick, New Jersey

Tanner M. Johanns, MD, PhDWashington University School of MedicineSt. Louis, Missouri

Daniel Hartman Johnson, MDMD Anderson Cancer CenterHouston, Texas

Aikaterini Kotrotsou, PhDMD Anderson Cancer CenterHouston, Texas

Amaia Lujambio, PhDIcahn School of Medicine at Mount SinaiNew York, New York

Netonia Marshall, PhDIcahn School of Medicine at Mount SinaiNew York, New York

MALE/FEMALE Ratio

42% 58%

9

Denis Migliorini, MDUniversity of PennslyvaniaPhiladelphia, Pennslyvania

Babak Moghimi, MDChildren’s Hospital of Los AngelesLos Angeles, California

Misako Nagasaka, MDKarmanos Cancer InstituteDetroit, Michigan

Hong Ha Rosa Nguyen, MDSt. Jude Children’s Research HospitalMemphis, Tennessee

Ke Pan, PhDMD Anderson Cancer CenterHouston, TX

Robin Parihar, MD, PhDBaylor College of MedicineHouston, Texas

Ravi Bhasker Patel, MD, PhDUniversity of WisconsinMadison, Wisconsin

Shabnum Patel, PhDThe George Washington UniversityWashington DC

Ivana Peran, PhDGeorgetown University Medical CenterWashington DC

Sarwish Rafiq, PhDMemorial Sloan Kettering Cancer CenterNew York, New York

Sangeetha Meda Reddy, MD, MSCIMD Anderson Cancer CenterHouston, Texas

Aaron Ring, MD, PhDYale University School of MedicineNew Haven, Connecticut

Dayana Rivadeneira, PhDUniversity of Pittsburgh Pittsburgh, Pennslyvania

Anthony Rongvaux, PhDFred Hutchinson Cancer Research CenterSeattle, Washington

2018 IOYIF Participants and Institutions

Participants’ Credentials

48%25%

27%

PhD

MD/DO

MD, PhD

10

Erin Lynn Schenk, MD, PhDMayo ClinicRochester, Minnesota

Triparna Sen, PhDMD Anderson Cancer CenterHouston, Texas

Tarsheen Kaur Sethi, MBBS, MDVanderbilt University Medical CenterNashville, Tennessee

Meenu Sharma, PhDMD Anderson Cancer CenterHouston, Texas

Rahul A. Sheth, MDMD Anderson Cancer CenterHouston, Texas

2018 IOYIF Participants and Institutions

Number of

INSTITUTIONS Represented

= 20

11

2018 IOYIF Professional Presentation Coaches

2018 IOYIF Expert Faculty Judges Mario Sznol, MD (Co-chair)Yale University School of MedicineNew Haven, Connecticut

Patrick Hwu, MD (Co-chair)The University of Texas MD Anderson Cancer CenterHouston, Texas

Helen E. Heslop, MDBaylor College of MedicineHouston Methodist Hospital/Texas Children’s HospitalHouston, Texas

Jeffrey S. Weber, MD, PhDNew York University Langone Medical CenterNew York, New York

Jennifer Wargo, MD, MMScThe University of Texas MD Anderson Cancer CenterHouston, Texas

Gordon J. Freeman, PhDDana-Farber Cancer InstituteHarvard Medical SchoolBoston, Massachusetts

Lisa H. Butterfield, PhDUniversity of Pittsburgh Cancer InstitutePittsburgh, Pennsylvania

Michael B. Atkins, MDGeorgetown-Lombardi Comprehensive Cancer CenterWashington, DC

Stephanie Roberson Barnard (Coach)Listen Write Present LLCGreensboro, North Carolina

Paul Casella (Coach)Health Care Communications GroupUniversity of Iowa Carver College of Medicine Iowa City, Iowa

Expert Faculty Judges. Top row (left to right): Jeffrey S. Weber, MD, PhD; Jennifer Wargo, MD, MMSc; Gordon J. Freeman, PhD; Lisa H. Butterfield, PhD. Bottom row (left to right): Michael B. Atkins, MD; Helen E. Heslop, MD; Patrick Hwu, MD; Mario Sznol, MD

12

2018 Updates from IOYIF Participants

RESEARCH PUBLICATIONS, NATIONAL MEETING PRESENTATIONS, AND AWARDS

JUNIOR FACULTY–RESEARCH SCIENTIST AND CLINICIAN SCIENTIST

Limo Chen, PhDPublicationChen L, Diao L, Yang Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Accepted for publication in Cancer Discovery.

FELLOWS–PHD/POST DOCTORAL AND CLINICAL FELLOW

Robyn D. Gartrell, MDPublication

Gartrell RD, Marks DK, Hart TD, et al. Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol Res. 2018;6(4):481–493.

Presentation

Gartrell RD, Marks DK, Hart TD, et al. Quantitative multiplex immunofluorescence (qmIF) and genomic evaluation of tumor microenvironment (TME) to identify candidate biomarkers in stage II/III melanoma. Abstract 9580. Presented at: 2018 ASCO Annual Meeting; June 4, 2018; Chicago, Illinois.

Gartrell RD, Chen A, Marks DK, et al. Quantitative compositional and spatial analysis of tumor microenvironment (TME) in primary melanoma. Abstract 2091. Presented at: 2018 AACR Annual Meeting; April 14–18, 2018; Chicago, Illinois.

Denis Migliorini, MDPresentation

Migliorini D, Shin HG, Liu F, et al. Universal Xenogeneic CAR T Cells: A Novel Translational Platform Using Gene Editing of Human Cart Cells to Target Canine Tumors. Abstract 780. Presented at: 2018 ASGCT Annual Meeting; May 16–19, 2018; Chicago, Illinois.

Hong Ha Rosa Nguyen, MDPresentation

Nguyen R, Rooney B, Federico SM, et al. Endogenous and Haploidentical Natural Killer Cell Reconstitution in Children Treated with Combined Chemoimmunotherapy For Neuroblastoma. Abstract 332. Presented at: ANR 2018; May 9–12, 2018; San Francisco, California.

Ravi B. Patel, MD, PhDAward

Conquer Cancer Foundation of ASCO/The Hayden Family Foundation Young Investigator Award for “Determining the dose and timing of systemic targeted radiation therapy with dual systemic checkpoint blockade.”

Shabnum Patel, PhDPresentation

Patel S, Chorvinsky E, Albihani S, et al. HIV-specific T cells generated from naive T cells can suppress HIV in vitro, display cytotoxicity, and recognize wide epitope breadths. Abstract S10. Presented at: 2018 ISCT Annual Meeting; May 2, 2018; Montreal, Canada.

13

HOW ATTENDING THE IOYIF WILL IMPACT YOUNG INVESTIGATORS’ CAREERS

“The scope of applications that has been proposed to me, along with potential collaborations, will be a great impact to my research.”

“Reinforcing collaborations and team science.”

“The coaching session was very helpful. The incredible part is networking with other young investigators doing immune-oncology!”

“Make research more patient oriented.”

“Potential future collaborations and improved quality of ongoing research.”

“Excellent contacts made! ”

2018 IOYIF Highlights PRESENTATION SKILLS ENHANCEMENT WORKSHOPTo augment the professional development aspects of the IOYIF, 2018 participants participated in individual coaching sessions by a team of experts from ListenWritePresent. Young Investigators who attended the one-on-one pre-program coaching sessions received expert advice and critique of their presentation and public speaking skills, and were given a copy of the book Writing, Speaking, & Communication Skills for Health Professionals, which was written by the ListenWritePresent team. In addition, the expert coaches provided participants with tips for effectively answering questions about and defending their research.

MENTORING MOMENTSDuring the meeting, members of the expert faculty judging panel provided “mentoring moment” ses-sions on the topics of grant writing, the academic promotion system, work-life balance, choosing the right mentor, publishing a scientific paper, and achieving success in academics without a lab. These sessions offered the opportunity for experts to share real-life career experiences and pearls for the young investigators.

A LITTLE BIRD TOLD ME...

14

5th annual

IMMUNO-ONCOLOGY Young Investigators’ Forum

Abstract submission deadline and details coming soon.

Please visit www.ioyif.com for more information and follow us

on Twitter @IOYIForum.

SAVE THE DATE!

April 25–28, 2019The Houstonian Hotel

Houston, Texas